SG11202112112UA - Anti-galectin-9 antibodies and uses thereof - Google Patents
Anti-galectin-9 antibodies and uses thereofInfo
- Publication number
- SG11202112112UA SG11202112112UA SG11202112112UA SG11202112112UA SG11202112112UA SG 11202112112U A SG11202112112U A SG 11202112112UA SG 11202112112U A SG11202112112U A SG 11202112112UA SG 11202112112U A SG11202112112U A SG 11202112112UA SG 11202112112U A SG11202112112U A SG 11202112112UA
- Authority
- SG
- Singapore
- Prior art keywords
- galectin
- antibodies
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4724—Lectins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962841732P | 2019-05-01 | 2019-05-01 | |
PCT/US2020/031181 WO2020223702A1 (en) | 2019-05-01 | 2020-05-01 | Anti-galectin-9 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202112112UA true SG11202112112UA (en) | 2021-11-29 |
Family
ID=73029403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202112112UA SG11202112112UA (en) | 2019-05-01 | 2020-05-01 | Anti-galectin-9 antibodies and uses thereof |
Country Status (8)
Country | Link |
---|---|
US (2) | US20220178930A1 (en) |
EP (1) | EP3962954A4 (en) |
JP (1) | JP2022531408A (en) |
CN (1) | CN114026126A (en) |
AU (1) | AU2020266677A1 (en) |
CA (1) | CA3138863A1 (en) |
SG (1) | SG11202112112UA (en) |
WO (2) | WO2020223704A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202003652QA (en) | 2017-10-27 | 2020-05-28 | Univ New York | Anti-galectin-9 antibodies and uses thereof |
US20240109968A1 (en) * | 2020-11-20 | 2024-04-04 | New York University | Anti-galectin-9 antibodies and therapeutic uses thereof |
IL308014A (en) * | 2021-04-30 | 2023-12-01 | Puretech Lyt Inc | Anti-galectin-9 antibodies and therapeutic uses thereof |
CA3233331A1 (en) * | 2021-10-01 | 2023-04-06 | Puretech Lyt, Inc. | Anti-galectin-9 antibodies and therapeutic uses thereof |
WO2024006933A1 (en) * | 2022-06-29 | 2024-01-04 | Puretech Lyt, Inc. | Treatment of hematological malignancies with antibodies inhibiting galectin-9 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1682159A4 (en) * | 2003-10-16 | 2010-07-21 | Stephen John Ralph | Immunomodulating compositions and uses therefor |
KR20070107687A (en) * | 2004-12-31 | 2007-11-07 | 제넨테크, 인크. | Polypeptides that bind br3 and uses thereof |
US20070237764A1 (en) * | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
ES2414804T3 (en) * | 2008-01-18 | 2013-07-22 | Genentech, Inc. | Methods and compositions that target polyubiquitin |
KR20110052642A (en) * | 2008-07-18 | 2011-05-18 | 오라제닉스, 인코포레이티드 | Compositions for the detection and treatment of colorectal cancer |
US8772457B2 (en) * | 2010-11-10 | 2014-07-08 | Genentech, Inc. | BACE1 antibodies |
WO2012077811A1 (en) * | 2010-12-09 | 2012-06-14 | 株式会社ガルファーマ | Galectin 9-secreting cell, production method for same, and application for same |
FR3021970B1 (en) * | 2014-06-06 | 2018-01-26 | Universite Sciences Technologies Lille | ANTIBODY AGAINST GALECTIN 9 AND INHIBITOR OF THE SUPPRESSIVE ACTIVITY OF T REGULATORY LYMPHOCYTES |
CA2966040A1 (en) * | 2014-11-04 | 2016-05-12 | Dana-Farber Cancer Institute, Inc. | Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses |
WO2017044308A1 (en) * | 2015-09-10 | 2017-03-16 | Albert Einstein College Of Medicine, Inc. | Synthetic antibodies to bax and uses thereof |
US20190292259A1 (en) * | 2016-05-24 | 2019-09-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd) |
SG11202003652QA (en) * | 2017-10-27 | 2020-05-28 | Univ New York | Anti-galectin-9 antibodies and uses thereof |
CA3134942A1 (en) * | 2019-03-25 | 2020-10-01 | New York University | Anti-galectin-9 antibodies and uses thereof |
-
2020
- 2020-05-01 WO PCT/US2020/031184 patent/WO2020223704A1/en active Application Filing
- 2020-05-01 CN CN202080047488.7A patent/CN114026126A/en active Pending
- 2020-05-01 WO PCT/US2020/031181 patent/WO2020223702A1/en unknown
- 2020-05-01 JP JP2021565064A patent/JP2022531408A/en active Pending
- 2020-05-01 AU AU2020266677A patent/AU2020266677A1/en active Pending
- 2020-05-01 SG SG11202112112UA patent/SG11202112112UA/en unknown
- 2020-05-01 EP EP20798582.1A patent/EP3962954A4/en active Pending
- 2020-05-01 CA CA3138863A patent/CA3138863A1/en active Pending
- 2020-05-01 US US17/607,879 patent/US20220178930A1/en active Pending
- 2020-05-01 US US17/607,878 patent/US20220185896A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3962954A4 (en) | 2023-01-18 |
AU2020266677A1 (en) | 2022-01-06 |
US20220185896A1 (en) | 2022-06-16 |
JP2022531408A (en) | 2022-07-06 |
CN114026126A (en) | 2022-02-08 |
WO2020223704A1 (en) | 2020-11-05 |
WO2020223702A1 (en) | 2020-11-05 |
US20220178930A1 (en) | 2022-06-09 |
CA3138863A1 (en) | 2020-11-05 |
EP3962954A1 (en) | 2022-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276950A (en) | Anti-cd73 antibodies and uses thereof | |
IL282968A (en) | Anti-nkg2a antibodies and uses thereof | |
SG11202105885WA (en) | Anti-claudin antibodies and uses thereof | |
IL289585A (en) | Dll3-targeting antibodies and uses thereof | |
IL275826A (en) | Anti-mct1 antibodies and uses thereof | |
ZA202006066B (en) | Anti-hla-g antibodies and use thereof | |
IL281297A (en) | Anti-npr1 antibodies and uses thereof | |
SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
SG11202112112UA (en) | Anti-galectin-9 antibodies and uses thereof | |
SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
IL280321A (en) | Anti-cxcr2 antibodies and uses thereof | |
IL277330A (en) | Anti-il-27 antibodies and uses thereof | |
IL287690A (en) | Anti-hvem antibodies and use thereof | |
IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
IL289656A (en) | Anti-tigit antibodies and application thereof | |
IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
IL281202A (en) | Anti-tnfrsf9 antibodies and uses thereof | |
IL277075A (en) | Anti-phf-tau antibodies and uses thereof | |
IL276548A (en) | Bcma-binding antibodies and uses thereof | |
IL283926A (en) | Anti-alpha-synuclein antibodies and uses thereof | |
IL291550A (en) | Anti-il-27 antibodies and uses thereof | |
IL291546A (en) | Anti-kir3dl3 antibodies and uses thereof | |
IL283890A (en) | Anti-periostin antibodies and uses thereof | |
SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
IL291280A (en) | Anti-cd371 antibodies and uses thereof |